5
2011
New Early Detection Test for Mesothelioma
Researchers at NYU Langone Medical Center in conjunction with the National Cancer Institute’s Early Detection Lab are working on a new protein test that will allow earlier detection of asbestos related pulmonary cancer. The test identifies proteins secreted from cancerous tumors, which are caused by asbestos. This test allows for earlier detection of mesothelioma , with researchers detecting 15 out of 19 cases with Stage 1 or Stage 2 malignant pleural mesothelioma.
Mesothelioma is a very aggressive pulmonary cancer that occurs only in individuals that have been exposed to asbestos or asbestos containing products. Victims often inhale the deadly product while working on various job sites. Although asbestos products have been banned in the United States, there is still a growing population being diagnosed with the disease. Mesothelioma can be fatal within 14 months of the diagnosis due to the advanced stage in which it is typically found. This test will allow for earlier detection and therefore better treatment options and longevity for victims of mesothelioma.
Lead researcher on the project, Harvery I. Pass, MD stated “the only patients that seem to benefit from therapy in mesothelioma are those that are found in stage 1, and this is only 10 to 15 percent of the patients.” When a patient is diagnosed in the later stages of mesothelioma the only care many doctors are able to provide is palliative care in order to improve the quality of life during their last days, this test will allow more patients the opportunity for chemotherapy, radiation, surgery, and other treatments.
For more information on this study please read the full article by clicking here. If you or a loved one has been diagnosed with mesothelioma or another asbestos related disease please visit our website or call us toll free at 1-800-970-DUST for a free legal consultation.
